IN THE HIGH COURT OF JHARKHAND AT RANCHI
Anil Kumar Choudhary, J.
Khushi Ram Agarwal, son of Jaikishan Lal Agarwal - Petitioner
Vs.
The State of Jharkhand - Opposite Party
Cr.M.P. No. 321 of 2023
Decided On : 05-09-2023
Section 482 Cr.P.C - Quashing of Criminal Proceeding - Drugs and Cosmetics Act, 1940 - Section 27 (C ) and 27 (d) - Section 17B (C) and 17 B (e ) read with Section 65 (5) (3) - Summary of Acts and Sections: The court discussed the provisions of the Drugs and Cosmetics Act, 1940, particularly focusing on the definition of spurious drugs under Section 17B and the procedure for inspection and analysis of drugs under Section 23. The interpretation of these provisions influenced the court's decision to dismiss the petition for quashing the criminal proceeding.
Fact of the Case:
The petitioners sought to quash criminal proceedings against them for alleged violations of the Drugs and Cosmetics Act, 1940. The allegations included selling a drug with a fictitious label and fake purchase documents.
Finding of the Court:
The court found that there was strong suspicion and prima facie evidence against the petitioners, and non-compliance with the inspection procedure under Section 23 of the Drugs and Cosmetics Act, 1940 was not fatal to the prosecution.
Issues: The issues revolved around the authenticity of the seized drug, compliance with inspection procedures, and the applicability of relevant legal provisions.
Ratio Decidendi: The court held that non-compliance with the inspection procedure under Section 23 of the Drugs and Cosmetics Act, 1940 was not fatal for the prosecution in cases involving allegations of spurious drugs.
Final Decision: The court dismissed the petition for quashing the criminal proceeding, finding strong suspicion against the petitioners based on the evidence presented.
JUDGMENT :
Heard the parties.
2. This criminal miscellaneous petition has been filed invoking the jurisdiction of this Court under Section 482 Cr.P.C. with a prayer for quashing the entire criminal proceeding and the order dated 18.07.2022 passed by learned Additional Sessions Judge- II- Cum-Special Judge, CBI-cum- Special Judge, (Cyber Crime Cases & Electricity Act Cases), Dhanbad in connection with Misc. Criminal Application No. 1262 of 2022 arising out of Drugs and Cosmetics Case no. 01 of 2021 whereby and whereunder learned Additional Sessions Judge-II has rejected the application filed under Section 227 of the CrPC by petitioners for their discharge in the case.
3. The allegation against the petitioners is that the Drug Inspector seized one articles in the name and style of Phencyrex Cough syrup (100 ML) Batch no. 33097-SMB1, manufacturing date Sep. 2017, Expiry Date – August, 2019 manufactured by M/s Smilex Healthcare Pvt. Ltd. -54, EPIP-1, Jharmajri, Baddi-174103, Dist.- Solan, H.P., Licence no. – L/15/1665/MNB seized from the establishment/shop of the accused M/s Baba Medical Agency, Dhanbad, of which, undisputedly, both the petitioners are the partners and the allegation that said Phencyrex Cough syrup was having fictitious and fake label of M/s Smilex Healthcare Pvt. Ltd, as the said company on the date of alleged manufacturing; as mentioned in label was not in operation on the said address as mentioned in the label, thus it is alleged that the said drug sold by petitioners, was not the product of the alleged manufacturer. It is further alleged that M/s Baba Medical Agency, Dhanbad even though provided the purchase documents of the Phencyrex Cough syrup from M/s Megha Medical but M/s Megha Medicals denied issuing any such purchase documents of the medicines in favour of M/s Baba Medicals. Learned Special Judge, Drugs and Cosmetics Act, on the basis of the materials placed before it, took cognizance for the offences punishable under Section 27 (C ) and 27 (d) of the Drugs and Cosmetics Act, 1940 for violation of Section 17B (C) and 17 B (e ) read with Section 65 (5) (3) of Drugs and Cosmetics Act, 1940 inter alia against the petitioners. The petitioners filed a petition for discharge under Section 227 of CrPC contending therein, that since the manufacturer company did not conclusively state that the sample is actually a counterfeit drug hence, in depth examination of the same is required to reach any conclusion and the ground of the contention of the Drug Inspector, that M/s Smilex Healthcare Pvt. Ltd, did not manufacture the same, is based on incomplete and insufficient information but subsequently, the said M/s Smilex Healthcare Pvt. Ltd, has intimated that it manufactured the said drug and the Drug Control Administration of Himachal Pradesh also, after inquiry in the matter and detail investigation , submitted a report to the complainant by merely mentioning that the seized drug has been manufactured by M/s Smilex Healthcare Pvt. Ltd.
4. The learned Special Judge, considered that the seized Phencyrex Cough syrup, from the petitioners, was stated to be manufactured in September, 2017 but as per the report dated 23.08.2019, the Drug Inspector, Solan, Himachal Pradesh, M/s Smilex Healthcare Pvt. Ltd. 54, EPIP-1, Jharmajri Baddi-174103, has wound up its business and was no longer operational on the said address of plot no. 54 since the year 2016 and on the date of manufacturing vide ‘control sample’, the company was operational from plot no. 23 with the remaining address being same. The manufacturer also confirmed vide letter dated 03.10.2018 and 28.01.2019 that the said product was not manufactured by them. Learned Special Judge, also considered that bare perusal of the label of the ‘control sample’ and the label of the seized sample annexed with the record, it is apparent that not only the plot number mentioned on both the labels i.e. 23 and 54 is different but also in the warning portion of the labels, which is statutor
Laborate Pharmaceuticals India Ltd vs. State of Tamil Nadu reported in AIR 2017 SC 2423
Non-compliance with inspection procedures under the Drugs and Cosmetics Act, 1940 is not fatal for prosecution in cases involving allegations of spurious drugs.
The right of the petitioner to adduce evidence under sub sections 3 and 4 of section 25 of the Drugs and Cosmetics Act was crucial in influencing the court's decision to quash the entire criminal pro....
Complaint for spurious drugs not quashable under CrPC 482 if allegations prima facie disclose offence; Magistrate takes cognizance of Chapter IV Drugs Act cases for committal to Sessions; manufacture....
The main legal point established in the judgment is that the inherent powers of the High Court should be exercised sparingly and with caution, and that the complaint disclosed a cognizable offence un....
The judgment establishes that a valuable right to re-test a drug sample, as provided under Section 25(4) of the Drugs and Cosmetics Act, cannot be denied without due process, and failure to comply wi....
Prosecution quashed for delay in sample testing beyond 60 days without extension under Rule 45 and failure to send sample to manufacturer under Section 23(4)(iii), depriving re-analysis right post sh....
The court established that the procedural requirements under Section 202 of the Code of Criminal Procedure do not apply to Sessions Judges, affirming their authority to take cognizance of cases under....
[The report of the Government Analyst under the Drugs and Cosmetics Act is conclusive unless challenged within 28 days, and compliance with the sampling procedure is mandatory.]
Login now and unlock free premium legal research
Login to SupremeToday AI and access free legal analysis, AI highlights, and smart tools.
Login
now!
India’s Legal research and Law Firm App, Download now!
Copyright © 2023 Vikas Info Solution Pvt Ltd. All Rights Reserved.